/ELOX
ELOX Stock - Eloxx Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.55
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELOX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-24.60
52W High$0.04
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-34,419,000 | $-66,018,000 | $-33,455,000 | $-50,555,000 | $-47,565,000 |
| Net Income | $-36,065,000 | $-66,727,000 | $-34,577,000 | $-50,874,000 | $-47,185,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-16.65 | $-38.15 | $-34.47 | $-53.46 | $-58.19 |
Company Overview
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ELOXBeat Rate
50%
Last 14 quarters
Avg Surprise
-5.8%
EPS vs Estimate
Beats / Misses
7/7
Last 12 quarters
Latest EPS
$-1.31
Q4 2023
EPS Surprise History
Q1 22
-16.7%
$-5.60vs$-4.80
Q2 22
-44.4%
$-5.20vs$-3.60
Q3 22
-20.0%
$-4.80vs$-4.00
Q4 22
+18.2%
$-3.60vs$-4.40
Q2 23
+1.7%
$-2.92vs$-2.97
Q2 23
-12.9%
$-2.88vs$-2.55
Q3 23
-27.3%
$-1.96vs$-1.54
Q4 23
+33.5%
$-1.31vs$-1.97
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 2, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Nov 22, 2024 | — | — | — | — |
Q3 2024 | Aug 16, 2024 | — | — | — | — |
Q2 2024 | May 27, 2024 | $-1.22 | — | — | — |
Q1 2024 | Mar 29, 2024 | $-1.22 | — | — | — |
Q4 2023 | Nov 13, 2023 | $-1.97 | $-1.31 | +33.5% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.54 | $-1.96 | -27.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-2.55 | $-2.88 | -12.9% | ✗ MISS |
Q2 2023 | Apr 3, 2023 | $-2.97 | $-2.92 | +1.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-4.40 | $-3.60 | +18.2% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-4.00 | $-4.80 | -20.0% | ✗ MISS |
Q2 2022 | May 6, 2022 | $-3.60 | $-5.20 | -44.4% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-4.80 | $-5.60 | -16.7% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-5.60 | $-4.40 | +21.4% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-5.20 | $-8.00 | -53.8% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-6.40 | $-8.80 | -37.5% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-8.80 | $-6.00 | +31.8% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $-7.60 | $-6.40 | +15.8% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-8.80 | $-8.00 | +9.1% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ELOX
What is ELOX's current stock price?
Eloxx Pharmaceuticals, Inc. (ELOX) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for ELOX?
No analyst price targets are currently available for this stock.
What sector is Eloxx Pharmaceuticals, Inc. in?
Eloxx Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ELOX's market cap?
Eloxx Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ELOX pay dividends?
No, Eloxx Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIOCQ
Biocept, Inc.
$0.00
Mkt Cap: $0.0B
CDXI
Cardax, Inc.
$0.00
Mkt Cap: $0.0B
HTGMQ
HTG Molecular Diagnostics, Inc.
$0.00
Mkt Cap: $0.0B
MDVLQ
MedAvail Holdings, Inc.
$0.00
Mkt Cap: $0.0B
MICRD
Micron Solutions, Inc.
$0.00
Mkt Cap: $0.0B
NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
NEXI
NexImmune, Inc.
$0.00
Mkt Cap: $0.0B
NMSCA
Nutrition Management Services Company
$0.00
Mkt Cap: $0.0B
OMDD
Ormand Industries Inc
$0.00
Mkt Cap: $0.0B
VRCI
Verde Science, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ELOX for comparison